OBJECTIVE: To describe the Alzheimer disease (AD)-like clinical and pathological features, including marked neurofibrillary tangle (NFT) pathology, of a familial prion disease due to a rare nonsense mutation of the prion gene (PRNP). METHODS: Longitudinal clinical assessments were available for the proband and her mother. After death, both underwent neuropathological evaluation. PRNP was sequenced after failure to find immunopositive Aβ deposits in the proband and the documentation of prion protein (PrP) immunopositive pathology. RESULTS: The proband presented at age 42 years with a 3-year history of progressive short-term memory impairment and depression. Neuropsychological testing found impaired memory performance, with relatively preserved attention and construction. She was diagnosed with AD and died at age 47 years. Neuropathologic evaluation revealed extensive limbic and neocortical NFT formation and neuritic plaques consistent with a Braak stage of VI. The NFTs were immunopositive, with multiple tau antibodies, and electron microscopy revealed paired helical filaments. However, the neuritic plaques were immunonegative for Aβ, whereas immunostaining for PrP was positive. The mother of the proband had a similar presentation, including depression, and had been diagnosed clinically and pathologically as AD. Reevaluation of her brain tissue confirmed similar tau and PrP immunostaining findings. Genetic analysis revealed that both the proband and her mother had a rare PRNP mutation (Q160X) that resulted in the production of truncated PrP. INTERPRETATION: We suggest that PRNP mutations that result in a truncation of PrP lead to a prolonged clinical course consistent with a clinical diagnosis of AD and severe AD-like NFTs.
OBJECTIVE: To describe the Alzheimer disease (AD)-like clinical and pathological features, including marked neurofibrillary tangle (NFT) pathology, of a familial prion disease due to a rare nonsense mutation of the prion gene (PRNP). METHODS: Longitudinal clinical assessments were available for the proband and her mother. After death, both underwent neuropathological evaluation. PRNP was sequenced after failure to find immunopositive Aβ deposits in the proband and the documentation of prion protein (PrP) immunopositive pathology. RESULTS: The proband presented at age 42 years with a 3-year history of progressive short-term memory impairment and depression. Neuropsychological testing found impaired memory performance, with relatively preserved attention and construction. She was diagnosed with AD and died at age 47 years. Neuropathologic evaluation revealed extensive limbic and neocortical NFT formation and neuritic plaques consistent with a Braak stage of VI. The NFTs were immunopositive, with multiple tau antibodies, and electron microscopy revealed paired helical filaments. However, the neuritic plaques were immunonegative for Aβ, whereas immunostaining for PrP was positive. The mother of the proband had a similar presentation, including depression, and had been diagnosed clinically and pathologically as AD. Reevaluation of her brain tissue confirmed similar tau and PrP immunostaining findings. Genetic analysis revealed that both the proband and her mother had a rare PRNP mutation (Q160X) that resulted in the production of truncated PrP. INTERPRETATION: We suggest that PRNP mutations that result in a truncation of PrP lead to a prolonged clinical course consistent with a clinical diagnosis of AD and severe AD-like NFTs.
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: B Ghetti; F Tagliavini; C L Masters; K Beyreuther; G Giaccone; L Verga; M R Farlow; P M Conneally; S R Dlouhy; B Azzarelli Journal: Neurology Date: 1989-11 Impact factor: 9.910
Authors: P Piccardo; B Ghetti; D W Dickson; H V Vinters; G Giaccone; O Bugiani; F Tagliavini; K Young; S R Dlouhy; C Seiler Journal: J Neuropathol Exp Neurol Date: 1995-11 Impact factor: 3.685
Authors: F Tagliavini; G Giaccone; F Prelli; L Verga; M Porro; J Q Trojanowski; M R Farlow; B Frangione; B Ghetti; O Bugiani Journal: Brain Res Date: 1993-07-09 Impact factor: 3.252
Authors: B Ghetti; P Piccardo; M G Spillantini; Y Ichimiya; M Porro; F Perini; T Kitamoto; J Tateishi; C Seiler; B Frangione; O Bugiani; G Giaccone; F Prelli; M Goedert; S R Dlouhy; F Tagliavini Journal: Proc Natl Acad Sci U S A Date: 1996-01-23 Impact factor: 11.205
Authors: F Tagliavini; F Prelli; M Porro; G Rossi; G Giaccone; M R Farlow; S R Dlouhy; B Ghetti; O Bugiani; B Frangione Journal: Cell Date: 1994-11-18 Impact factor: 41.582
Authors: Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind Journal: Cold Spring Harb Perspect Biol Date: 2018-05-01 Impact factor: 10.005
Authors: Ryan A Townley; Angelina J Polsinelli; Julie A Fields; Mary M Machulda; David T Jones; Jonathan Graff-Radford; Kejal M Kantarci; Val J Lowe; Rosa V Rademakers; Matt C Baker; Neeraj Kumar; Bradley F Boeve Journal: Neurocase Date: 2020-06-30 Impact factor: 0.881
Authors: P Piccardo; J Cervenak; O Yakovleva; L Gregori; K Pomeroy; A Cook; F S Muhammad; T Seuberlich; L Cervenakova; D M Asher Journal: J Comp Pathol Date: 2011-10-20 Impact factor: 1.311
Authors: Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-01 Impact factor: 3.568